China Accepts Ocumension Therapeutics' Biologic License Application For Eye Drug; Shares Up 3%
China Accepts Ocumension Therapeutics' Biologic License Application For Eye Drug; Shares Up 3%
中國批准了Ocumension Therapeutics的生物製品許可申請,用於眼睛藥物; 股票上漲3%。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊